Many patients with incontinence do not need surgery – for these patients symptoms can often be considerably improved by conservative measures, including drugs. Several different pharmacological actions are potentially useful depending on the underlying cause of the incontinence: a) Detrusor instability (DI) responds to drugs reducing bladder contractility: Anticholinergic agents, e.g. oxybutynin and tolterodine, act at postganglionic parasympathetic cholinergic receptor sites on the detrusor muscle, reducing the strength of the detrusor contraction. Tricyclic antidepressants, e.g. imipramine, have anticholinergic effects, block presynaptic uptake of amine neurotransmitters and directly inhibit detrusor muscle. Alpha-adrenergic antagonists may have a role to play by dual actions on bladder overactivity (due to altered receptor function) and by reducing outlet resistance. b) Genuine stress incontinence (GSI) may be treated using alpha-adrenergic agonists, e.g. phenylpropanolamine, to increase outlet resistance by stimulating smooth muscle of the urethra and bladder neck. c) In nocturnal enuresis reduction of nocturnal urine output with the anti-diuretic hormone (ADH) analogue DDAVP (1-deamino, 8-arginine vasopressin) is beneficial. d) Bladder emptying may be facilitated in patients with retention and ‘overflow’ incontinence by alpha-adrenergic antagonists, which reduce outlet resistance, and perhaps by parasympathomimetics, e.g. bethanecol. e) In postmenopausal women, systemic oestrogen replacement reduces filling symptoms including urge incontinence. Evidence for oestrogen replacement alone in GSI is lacking, but combination with alpha-agonists is beneficial in milder GSI.For the future, tolterodine and other new anticholinergics offer the hope of treatment for DI with fewer of the side effects that limit the use of established drugs. Better understanding of the pathophysiology of DI may provide new targets for drug therapy, such as hyperpolarisation of detrusor muscle membrane. Alpha-agonists may find a greater role in the future, as may ADH analogues for noctural symptoms.

Keywords:
Pharmacological treatment, Urinary incontinence, Detrusor instability, Bladder overactivity, Urge incontinence, Genuine stress incontinence, Nocturnal enuresis
1.
Witjes WPJ, De la Rosette JJMCH, Donovan JL, Peters TJ, Abrams P, Kay HE, Höfner K, Kinn A-C, Walter S, and the International Continence Society ‘Benign Prostatic Hyperplasia’ study group: The International Continence Society ‘Benign Prostatic Hyperplasia’ study: the bothersomeness of urinary symptoms. J Urol 1997;157:885–889.
2.
Andersson K-E: The overactive bladder: pharmacological basis of drug treatment. Urology 1997;50(suppl 6A):74–84.
3.
Wein AJ: Neuromuscular dysfunction of the lower urinary tract and its treatment. Chapter 29; in Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds): Campbell’s Urology (7th Ed). Philadelphia, WB Saunders Company, 1998, pp 953–1006.
4.
Abrams P, Freeman R, Anderström C, Mattiasson A: Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801–810.
5.
Thuroff J, Burke B, Ebner A, Faber P, De Geeter P, Hannapel J, Heidler H, Madersbacher H, Melchior H, Schäfer W et al: Randomized, double-blind multicentre trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs propantheline vs placebo. J Urol 1991;145:813–816.
6.
Weese Dl, Roskamp DA, Leach GE, Zimmern PE: Intravesical oxybutynin hydrochloride: experience with 42 patients. Urology 1993;41(6):527–530.
7.
Castleden CM, George CF, Renwick AG, Asher MJ: Imipramine – a possible alternative to current therapy for urinary incontinence in the elderly. J Urol 1981;125(3):318–320.
8.
Abrams P: Terodiline in clinical practice. Urology 1990;36(suppl):60.
9.
Perlberg S, Caine M: Adrenergic response of bladder muscle in prostatic obstruction. Urology 1982;20(5):524–527.
10.
Chapple CR: The role of neural factors in prostatic obstruction and the pathogenesis of secondary detrusor instability. University of London: MD Thesis 1990.
11.
Lepor H, Theune C: Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. J Urol 1995;154:116–118.
12.
Serels S, Stein M: Prospective study comparing hyoscyamine, doxazosin, and combination therapy for the treatment of urgency and frequency in women. Neurourol Urodyn 1998;17:31–36.
13.
Nurse D, Restorick J, Mundy A: The effect of cromakalim on the normal and hyperreflexic human detrusor muscle. Br J Urol 1991;68:27–31.
14.
Howe BB, Halterman TJ, Yochim CL, Do ML, Pettinger SJ, Ohnmacht CJ, Russell K, Empfield JR, Trainor DA et al: Zeneca ZD 6169: a novel KATP channel opener with in vivo selectivity for urinary bladder. J Pharmacol Exp Ther 1995;274(2):884–890.
15.
Castleden CM, Morgan B: The effect of beta adrenoceptor antagonists on urinary incontinence in the elderly. Br J Clin Pharmacol 1980;10:619–620.
16.
Truss M, Stief CC, Uckert S, Becker AJ, Forssmann W-G, Jonas U: Initial clinical experience with the selective phosphodiesterase (PDE)-1 isoenzyme inhibitor vinpocetine in the treatment of urge-incontinence and low compliance bladder (abstract). J Urol 1997;157(suppl 4):187.
17.
Maggi CA, Barbanti G, Santiciolo P, Beneforti P, Misuri D, Meli A, Turini D : Cystometric evidence that capsaicin-sensitive nerves modulate the afferent branch of the micturition reflex in humans. J Urol 1989;142(1):150–154.
18.
Diokno A, Taub M: Ephedrine in treatment of urinary incontinence. Urology 1975;5(5):624–625.
19.
Awad SA, Downie JW, Kirulata HG: Alpha adrenergic agents in urinary disorders of the proximal urethra. Part I: Sphincteric Incontinence. Br J Urol 1978;50:332–335.
20.
Collste L, Lindskog M: Phenylpropanolamine in treatment of female stress urinary incontinence. Double-blind placebo-controlled study in 24 patients. Urology 1987;30(4):398–403.
21.
Bhatia NN, Bergman AM, Karram MM: Effects of estrogen on urethral function in women with urinary incontinence. Am J Obstet Gynecol 1989;160(1):176–181.
22.
Hilton P, Stanton SL: The use of intravaginal oestrogen cream in genuine stress incontinence. Br J Obstet Gynaecol 1983;90(10):940–944.
23.
Fantl A, Cardozo L, McClish D: Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1994;83 (1):12–18.
24.
Jackson S, Shepherd A, Abrams P: Does oestrogen supplementation improve the symptoms of postmenopausal urinary stress incontinence? Neurourol Urodyn 1997;16(5):350–351.
25.
Norgaard JP, Rillig S, Djurhuus JC: Nocturnal enuresis: an approach to treatment based on pathogenesis. J Pediatr 1989;114(4 pt 2):705–710.
26.
Kinn AC, Larsson PO: Desmopressin: a new principle for symptomatic treatment of urgency and incontinence in patients with multiple sclerosis. Scand J Urol Nephrol 1990;24(2):109–112.
27.
Reynard J, Cannon A, Yang Q, Abrams P: A novel therapy for nocturnal polyuria: a double-blind, randomised trial of frusemide versus placebo. Br J Urol 1998; Feb.
28.
Andersson K-E: Current concepts in the treatment of disorders of micturition. Drugs 1988;35(4):477–494.
29.
Sullivan J, Abrams P: Alpha adrenergic antagonists in neurogenic lower urinary tract dysfunction. Urology 1998 (in press).
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.